On 31 October 2023, Radiopharm Theranostics Limited (ASX:RAD) (Radiopharm or Company) announced the details of a non-renounceable entitlement offer (Entitlement Offer) to raise approximately $10 million. Under the Entitlement Offer, eligible shareholders were able to subscribe for 1 new fully paid ordinary share in Radiopharm (New Shares) for every 2.35 fully paid ordinary shares in Radiopharm at the issue price of $0.07 per New Share. Radiopharm received valid applications under the Entitlement Offer for 30,197,244 New Shares, raising an amount of approximately $2.1 million.
Radiopharm is pleased to advise it has received commitments totalling approximately A$1.7 million for the Shortfall under the Entitlement Offer. The 24,025,716 New Shares will be issued at the same price per share as the Entitlement Offer being $0.07 per New Share and will rank equally in all respects with existing shares on issue. Funds will be used to support the company’s clinical programs.
For more information, download the attached PDF.
Download this document
